 "Claris rallies on getting nod for Furosemide injection in US")
Claris Lifesciences has moved higher by 8% to Rs 238 on the BSE after the company announced that it has received the Prior Approval Supplement (PAS) for furosemide injection in the United States of America (US).
The company received the original approval for this Abbreviated New Drug Application (ANDA) in January 2014 and was selling the products in the USA in 2014. But since January 2015, the company has been facing supply issues from its raw material supplier and has not been able to supply its products to the USA, Claris Lifesciences said in a statement.
The company has filed a PAS application to append an additional supplier to the ANDA; this process was done for redundancy and to ensure a consistent supply of the API for its finished formulation sold in the USA. With this approval, alternative vendor has been appended to the ANDA and this will allow the company to recommence its supplies to the USA, Claris Lifesciences added.
At 12:21 PM, the stock was up 5% at Rs 232 on the BSE. Around 228,000 shares changed hands on the counter so far as against an average 194,000 shares traded daily in the past two weeks on the BSE.
The company received the original approval for this Abbreviated New Drug Application (ANDA) in January 2014 and was selling the products in the USA in 2014. But since January 2015, the company has been facing supply issues from its raw material supplier and has not been able to supply its products to the USA, Claris Lifesciences said in a statement.
The company has filed a PAS application to append an additional supplier to the ANDA; this process was done for redundancy and to ensure a consistent supply of the API for its finished formulation sold in the USA. With this approval, alternative vendor has been appended to the ANDA and this will allow the company to recommence its supplies to the USA, Claris Lifesciences added.
At 12:21 PM, the stock was up 5% at Rs 232 on the BSE. Around 228,000 shares changed hands on the counter so far as against an average 194,000 shares traded daily in the past two weeks on the BSE.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%